**Core Concept**
The question is testing the concept of intravascular thrombolysis, specifically the cellular source of plasminogen activators that facilitate the breakdown of fibrin clots in the coronary arteries. This process is crucial in the management of acute myocardial infarction (AMI), as it helps to restore blood flow to the affected myocardium.

**Why the Correct Answer is Right**
Intravascular thrombolysis is mediated by plasminogen activators, which convert plasminogen into plasmin, a potent fibrinolytic enzyme. Plasmin then breaks down fibrin clots, restoring blood flow to the occluded coronary artery. The primary source of plasminogen activators in this scenario is endothelial cells, which release tissue-type plasminogen activator (t-PA) in response to injury. This release of t-PA triggers the intravascular thrombolysis process, helping to dissolve the occluding thrombus.

**Why Each Wrong Option is Incorrect**
* **Option A:** Macrophages do contribute to fibrinolysis by releasing plasminogen activator inhibitor-1 (PAI-1), which inhibits plasminogen activators. However, they are not the primary source of plasminogen activators in this scenario.
* **Option B:** Platelets are involved in clot formation, not fibrinolysis. They release various factors that promote thrombus formation, including thromboxane A2 and ADP.
* **Option C:** Smooth muscle cells can produce plasminogen activators, but their role is more relevant in the context of atherosclerotic plaque stabilization rather than acute thrombolysis.

**Clinical Pearl / High-Yield Fact**
The administration of t-PA within 3 hours of symptom onset is a Class I indication for acute myocardial infarction, as it significantly improves outcomes by restoring blood flow to the affected myocardium.

**Correct Answer:** C.